CDK9 and cerebral malaria: Regarding the experimental cerebral malaria model, TaK also showed low antiplasmodial activity compared to TaD which limited parasite growth from 89% at Day 7 compared to 35% for TaK. In addition, treatment with TaD prevented premature death in mice and maintained 50% survival up to Day 20 unlike TaK whose treatment had no effect on death prevention in this model.